CIK: 0001937964
Total reported value
$499.4M
Reporting period: 2026-03-31 · Number of holdings: 50
Artia Global Partners LP disclosed 50 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $499.4M and a quarterly turnover rate of 60.3%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "A"
Artia Global Partners LP's disclosed holdings carry a Herfindahl concentration index of 0.123 — mathematically equivalent to about 8 equally-sized positions, well below its 50 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 2.26), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 60% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim SLNOEUR
-88.3% -$24.7M
Trim ARGX
-54.0% -$32.7M
Add INSM
-17.6% -$43.3M
Trim VKTX
-74.9% -$19.4M
Add ABVX
-1.6% -$15.5M
Add DNTH
-20.5% $5.2M
Showing top 49 holdings (of 50 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed INC | Stock-Healthcare | 29.74% | +2.56% | -17.58% | |
| 2 | ABVX | Abivax Sa-adr | Stock-Other | 13.39% | +1.72% | -1.62% | |
| 3 | LLY | Eli Lilly & Co | Stock-Healthcare | 7.04% | -0.65% | -24.32% | |
| 4 | TRVI | Trevi Therapeutics INC | Stock-Other | 4.81% | +1.24% | — | |
| 5 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.35% | -3.36% | -54.03% | |
| 6 | AZN | AstraZeneca PLC | Stock-Healthcare | 3.77% | +3.77% | NEW | |
| 7 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 3.23% | +0.73% | — | |
| 8 | DNTH | Dianthus Therapeutics INC | Stock-Other | 2.74% | +1.54% | -20.53% | |
| 9 | RVMD | Revolution Medicines INC | Stock-Healthcare | 2.43% | +1.25% | +19.96% | |
| 10 | IONS | Ionis Pharmaceuticals INC | Stock-Healthcare | 2.17% | +0.55% | — | |
| 11 | MRNA | Moderna INC | Stock-Healthcare | 2.03% | +2.03% | NEW | |
| 12 | EYPT | Eyepoint INC | Stock-Other | 1.98% | -0.01% | — | |
| 13 | DGX | Quest Diagnostics INC | Stock-Healthcare | 1.60% | +0.60% | — | |
| 14 | ALMS | Alumis INC | Stock-Other | 1.43% | +1.43% | NEW | |
| 15 | VKTX | Viking Therapeutics INC | Stock-Healthcare | 1.18% | -2.41% | -74.88% | |
| 16 | MRK | Merck & Co. INC. | Stock-Healthcare | 1.12% | +1.12% | NEW | |
| 17 | 430 | Terns Pharmaceuticals INC | Stock-Other | 1.11% | +1.11% | NEW | |
| 18 | JNJ | Johnson & Johnson | Stock-Healthcare | 1.11% | +1.11% | NEW | |
| 19 | SION | Sionna Therapeutics INC | Stock-Other | 0.96% | — | — | |
| 20 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.95% | +0.35% | — | |
| 21 | RAPP | Rapport Therapeutics INC | Stock-Other | 0.87% | — | — | |
| 22 | ASND | Ascendis Pharma A/S | Stock-Other | 0.81% | — | — | |
| 23 | BLTE | Belite Bio INC - Adr | Stock-Other | 0.80% | +0.39% | +38.91% | |
| 24 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 0.76% | +0.51% | +62.50% | |
| 25 | MLYS | Mineralys Therapeutics INC | Stock-Other | 0.75% | +0.04% | — | |
| 26 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.72% | +0.32% | — | |
| 27 | PALI | Palisade Bio INC | Stock-Other | 0.70% | +0.04% | — | |
| 28 | BIIB | Biogen INC | Stock-Healthcare | 0.68% | +0.68% | NEW | |
| 29 | PROK | Prokidney CORP | Stock-Other | 0.65% | +0.07% | -1.71% | |
| 30 | ABBV | Abbvie INC | Stock-Healthcare | 0.63% | — | — | |
| 31 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.59% | +0.24% | — | |
| 32 | DRUG | Bright Minds Biosciences INC | Stock-Other | 0.56% | — | +14.97% | |
| 33 | PTGX | Protagonist Therapeutics INC | Stock-Other | 0.48% | +0.20% | -0.09% | |
| 34 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 0.46% | -3.37% | -88.27% | |
| 35 | BTSG | Brightspring Health Services | Stock-Other | 0.46% | +0.24% | +29.33% | |
| 36 | TVTX | Travere Therapeutics INC | Stock-Other | 0.42% | +0.04% | — | |
| 37 | EWTX | Edgewise Therapeutics INC | Stock-Other | 0.41% | +0.41% | NEW | |
| 38 | CELC | Celcuity INC | Stock-Other | 0.36% | +0.18% | +20.74% | |
| 39 | BBIO | Bridgebio Pharma INC | Stock-Healthcare | 0.30% | — | — | |
| 40 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.28% | — | — | |
| 41 | CYTK | Cytokinetics INC | Stock-Healthcare | 0.22% | +0.22% | NEW | |
| 42 | ELVN | Enliven Therapeutics INC | Stock-Other | 0.16% | +0.16% | NEW | |
| 43 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.16% | — | — | |
| 44 | TENX | Tenax Therapeutics INC | Stock-Other | 0.13% | — | — | |
| 45 | KOD | Kodiak Sciences INC | Stock-Other | 0.13% | — | — | |
| 46 | NUVL | Nuvalent Inc-a | Stock-Other | 0.10% | -0.02% | -39.51% | |
| 47 | APGE | Apogee Therapeutics INC | Stock-Other | 0.10% | +0.10% | NEW | |
| 48 | AVTX | Avalo Therapeutics INC | Stock-Other | 0.09% | -0.02% | -30.31% | |
| 49 | PEPG | Pepgen INC | Stock-Other | 0.07% | -0.12% | — |
Performance for Q3 2026
+3.7%
Performance Last 4 Quarters
-15.8%
Based on 77% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 50 | $499.4M | 60 | |
| 2025-12-31 | 55 | $705.8M | 68 | |
| 2025-09-30 | 51 | $630.9M | 100 | |
| 2025-06-30 | 37 | $415.6M | 0 | |
| 2025-03-31 | 38 | $395.1M | 0 | |
| 2024-12-31 | 37 | $279.8M | 0 | |
| 2024-09-30 | 45 | $366.9M | 0 | |
| 2024-06-30 | 46 | $517.3M | 0 | |
| 2024-03-31 | 49 | $497.5M | 0 | |
| 2023-12-31 | 31 | $343.7M | 0 | |
| 2023-09-30 | 27 | $240.6M | 0 | |
| 2023-06-30 | 34 | $290.1M | 0 | |
| 2023-03-31 | 36 | $270.6M | 0 | |
| 2022-12-31 | 25 | $262.4M | 0 |
Artia Global Partners LP's most significant position changes for 2026-03-31: Sold out: Proshares Ultra Gold (UGL); Sold out: uniQure N.V. (QURE); New buy: AstraZeneca PLC (AZN); Sold out: Astrazeneca Plc-spons Adr (AZNN); Sold out: Cidara Therapeutics INC (CDTX).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed INC | +2.6% | -17.58% | Trim |
| 2 | ABVX | Abivax Sa-adr | +1.7% | -1.62% | Trim |
| 3 | DNTH | Dianthus Therapeutics INC | +1.5% | -20.53% | Trim |
| 4 | RVMD | Revolution Medicines INC | +1.3% | +19.96% | Add |
| 5 | TRVI | Trevi Therapeutics INC | +1.2% | — | Unchanged |
| 6 | NAMS | NewAmsterdam Pharma Company N.V. | +0.7% | — | Unchanged |
| 7 | DGX | Quest Diagnostics INC | +0.6% | — | Unchanged |
| 8 | IONS | Ionis Pharmaceuticals INC | +0.6% | — | Unchanged |
| 9 | XENE | Xenon Pharmaceuticals INC | +0.5% | +62.50% | Add |
| 10 | BLTE | Belite Bio INC - Adr | +0.4% | +38.91% | Add |
| 11 | SRRK | Scholar Rock Holding CORP | +0.4% | — | Unchanged |
| 12 | ROIV | Roivant Sciences Ltd. | +0.3% | — | Unchanged |
| 13 | BTSG | Brightspring Health Services | +0.2% | +29.33% | Add |
| 14 | UTHR | United Therapeutics CORP | +0.2% | — | Unchanged |
| 15 | PTGX | Protagonist Therapeutics INC | +0.2% | -0.09% | Trim |
| 16 | CELC | Celcuity INC | +0.2% | +20.74% | Add |
| 17 | PROK | Prokidney CORP | +0.1% | -1.71% | Trim |
| 18 | MLYS | Mineralys Therapeutics INC | 0% | — | Unchanged |
| 19 | PALI | Palisade Bio INC | 0% | — | Unchanged |
| 20 | TVTX | Travere Therapeutics INC | 0% | — | Unchanged |
| 21 | EYPT | Eyepoint INC | 0% | — | Unchanged |
| 22 | AVTX | Avalo Therapeutics INC | 0% | -30.31% | Trim |
| 23 | NUVL | Nuvalent Inc-a | 0% | -39.51% | Trim |
| 24 | PEPG | Pepgen INC | -0.1% | — | Unchanged |
| 25 | LLY | Eli Lilly & Co | -0.7% | -24.32% | Trim |
| 26 | VKTX | Viking Therapeutics INC | -2.4% | -74.88% | Trim |
| 27 | ARGX | Argenx Se - Adr | -3.4% | -54.03% | Trim |
| 28 | SLNOEUR | Soleno Therapeutics INC | -3.4% | -88.27% | Trim |
| 29 | UGL | Proshares Ultra Gold | — | EXIT | Sold out |
| 30 | QURE | uniQure N.V. | — | EXIT | Sold out |
| 31 | AZN | AstraZeneca PLC | — | NEW | New buy |
| 32 | AZNN | Astrazeneca Plc-spons Adr | — | EXIT | Sold out |
| 33 | CDTX | Cidara Therapeutics INC | — | EXIT | Sold out |
| 34 | MRNA | Moderna INC | — | NEW | New buy |
| 35 | ALMS | Alumis INC | — | NEW | New buy |
| 36 | ALNY | Alnylam Pharmaceuticals INC | — | EXIT | Sold out |
| 37 | VTYXUSD | Ventyx Biosciences INC | — | EXIT | Sold out |
| 38 | PVLA | Palvella Therapeutics INC | — | EXIT | Sold out |
| 39 | MRK | Merck & Co. INC. | — | NEW | New buy |
| 40 | 430 | Terns Pharmaceuticals INC | — | NEW | New buy |
| 41 | JNJ | Johnson & Johnson | — | NEW | New buy |
| 42 | RNAGBP | Avidity Biosciences INC | — | EXIT | Sold out |
| 43 | BIIB | Biogen INC | — | NEW | New buy |
| 44 | OCUL | Ocular Therapeutix INC | — | EXIT | Sold out |
| 45 | EWTX | Edgewise Therapeutics INC | — | NEW | New buy |
| 46 | UPB | Upstream Bio INC | — | EXIT | Sold out |
| 47 | CYTK | Cytokinetics INC | — | NEW | New buy |
| 48 | ELVN | Enliven Therapeutics INC | — | NEW | New buy |
| 49 | ANRO | Alto Neuroscience INC | — | EXIT | Sold out |
| 50 | APGE | Apogee Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | Amendment | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001114702
Total reported value
$499.4M
161 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001423045
Total reported value
$499.4M
211 stks
2026-06-30
AUM within 0.0% of this institution
CIK 0002008666
Total reported value
$499.6M
166 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001493215
Total reported value
$10.0B
88 stks
2026-03-31
2 of the top 5 holdings overlap, including Insmed INC
CIK 0001595725
Total reported value
$1.7B
100 stks
2026-03-31
2 of the top 5 holdings overlap, including Eli Lilly & Co
CIK 0001599882
Total reported value
$810.5M
86 stks
2026-03-31
2 of the top 5 holdings overlap, including Eli Lilly & Co